Roslyn Bernstein Mannon

Roslyn Bernstein Mannon

Auto-generated profile, based on publicly available information

Roslyn Bernstein Mannon

University of Nebraska Medical Center, Omaha, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2020 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ALAlexandre Loupy
Alexandre Loupy
MHMark Haas
Mark Haas
CRCandice Roufosse
Candice Roufosse
MNMaarten Naesens
Maarten Naesens
BABenjamin Alexander Adam
Benjamin Alexander Adam
MMMichael H Mengel
Michael H Mengel
The XV. Banff conference for allograft pathology was held in conjunction with the annual meeting of the American Society for Histocompatibility and Immunogenetics in Pittsburgh, PA (USA) and focused on refining recent updates to the classification, advances from the Banff working groups, and standardization of molecular diagnostics. This report on kidney transplant pathology details clarifications and refinements to the criteria for chronic active (CA) T cell–mediated rejection (TCMR), borderline, and antibody‐mediated rejection (ABMR). The main focus of kidney sessions was on how to address biopsies meeting criteria for CA TCMR plus borderline or acute TCMR. Recent studies on the clinical impact of borderline infiltrates were also presented to clarify whether the threshold for interstitial inflammation in diagnosis of borderline should be i0 or i1. Sessions on ABMR focused on biopsies showing microvascular inflammation in the absence of C4d staining or detectable donor‐specific antibodies; the potential value of molecular diagnostics in such cases and recommendations for use of the latter in the setting of solid organ transplantation are presented in the accompanying meeting report. Finally, several speakers discussed the capabilities of artificial intelligence and the potential for use of machine learning algorithms in diagnosis and personalized therapeutics in solid organ transplantation.

2 July 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SRSunad Rangarajan
Sunad Rangarajan
NBNathaniel B. Bone
Nathaniel B. Bone
AZAnna A. Zmijewska
Anna A. Zmijewska
SJShaoning Jiang
Shaoning Jiang
DPDae Won Park
Dae Won Park
JZJaroslaw W. Zmijewski
Jaroslaw W. Zmijewski

11 February 2005 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JPJonathan P. Pearl
Jonathan P. Pearl
JPJeremy Parris
Jeremy Parris
DHDouglas A. Hale
Douglas A. Hale
SHSteven C. Hoffmann
Steven C. Hoffmann
WBWendy B. Bernstein
Wendy B. Bernstein
AKAllan D. Kirk
Allan D. Kirk
T-cell depletion facilitates reduced immunosuppression following organ transplantation and has been suggested to be pro-tolerant. However, the characteristics of post-depletional T cells have not been evaluated as they relate to tolerance induction. We therefore studied patients undergoing profound T-cell depletion with alemtuzumab or rabbit anti-thymocyte globulin following renal transplantation, evaluating the phenotype and functional characteristics of their residual cells. Naïve T cells and T cells with potential regulatory function (CD4+CD25+) were not prevalent following aggressive depletion. Rather, post-depletion T cells were of a single phenotype (CD3+CD4+CD45RA-CD62L-CCR7-) consistent with depletion-resistant effector memory T cells that expanded in the first month and were uniquely prevalent at the time of rejection. These cells were resistant to steroids, deoxyspergualin or sirolimus in vitro, but were calcineurin-inhibitor sensitive. These data demonstrate that therapeutic depletion begets a limited population of functional memory-like T cells that are easily suppressed with certain immunosuppressants, but cannot be considered uniquely pro-tolerant.

27 October 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
MNMaarten Naesens
Maarten Naesens
CRCandice Roufosse
Candice Roufosse
MHMark Haas
Mark Haas
CLCarmen Lefaucheur
Carmen Lefaucheur
RMRoslyn B. Mannon
Roslyn B. Mannon
MMMichael H Mengel
Michael H Mengel
The XVI-th Banff Meeting for Allograft Pathology was held in Banff, Alberta, Canada, from 19th-23rd September 2022, as a joint meeting with the Canadian Society of Transplantation. To mark the 30th anniversary of the first Banff Classification, pre-meeting discussions were held on the past, present, and future of the Banff Classification. This report is a summary of the meeting highlights that were most important in terms of their effect on the Classification, including discussions around microvascular inflammation and biopsy-based transcript analysis for diagnosis. In a post-meeting survey, agreement was reached on the delineation of the following phenotypes: (1) "Probable antibody-mediated rejection (AMR)", which represents DSA-positive cases with some histological features of AMR but below current thresholds for a definitive AMR diagnosis; and (2) "Microvascular inflammation (MVI), DSA-negative and C4d-negative", a phenotype of unclear cause requiring further study, which represents cases with MVI not explained by DSA. Although biopsy-based transcript diagnostics are considered promising and remain an integral part of the Banff Classification (limited to diagnosis of AMR), further work needs to be done to agree on the exact classifiers, thresholds, and clinical context of use.

27 August 2010 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
RMR. B. Mannon
R. B. Mannon
AMA. J. Matas
A. J. Matas
JGJ. Grande
J. Grande
RLR. Leduc
R. Leduc
JCJ. Connett
J. Connett
FIfor the DeKAF Investigators
for the DeKAF Investigators
The Banff scoring schema provides a common ground to analyze kidney transplant biopsies. Interstitial inflammation (i) and tubulitis (t) in areas of viable tissue are features in scoring acute rejection, but are excluded in areas of tubular atrophy (TA). We studied inflammation and tubulitis in a cohort of kidney transplant recipients undergoing allograft biopsy for new‐onset late graft dysfunction (N = 337). We found inflammation (‘iatr’) and tubulitis (‘tatr’) in regions of fibrosis and atrophy to be strongly correlated with each other (p < 0.0001). Moreover, iatr was strongly associated with death‐censored graft failure when compared to recipients whose biopsies had no inflammation, even after adjusting for the presence of interstitial fibrosis (Hazard Ratio = 2.31, [1.10–4.83]; p = 0.0262) or TA (hazard ratio = 2.42, [1.16–5.08]; p = 0.191), serum creatinine at the time of biopsy, time to biopsy and i score. Further, these results did not qualitatively change after additional adjustments for C4d staining or donor specific antibody. Stepwise regression identified the most significant markers of graft failure which include iatr score. We propose that a more global assessment of inflammation in kidney allograft biopsies to include inflammation in atrophic areas may provide better prognostic information. Phenotypic characterization of these inflammatory cells and appropriate treatment may ameliorate late allograft failure.

13 July 2018 in Nephron
Verified
Journal Article
Closed access
PDF file
RMRoslyn B. Mannon
Roslyn B. Mannon
With the growing wait list of individuals waiting for kidney transplantation, there has been renewed interest in the quality and function of donor organs. In particular, concern about the development of delayed allograft function (DGF) after transplantation continues to lead to the avoidance of donor organs offered to a transplant center. DGF is associated with worse short-and long-term outcomes and associated with higher rejection rates. There are no FDA-approved therapies to mitigate the ischemic injury that occurs. Risk factors include both donor and recipient characteristics, although their prediction is not precise. With new understanding about mechanisms of injury and new focus on the function of the deceased donor, there is opportunity to identify not only novel therapies to improve allograft function but to identify potential biomarkers of DGF. DGF remains a significant factor in impacting kidney transplant outcome, and finding biomarkers will assist in the development and approval of novel agents to ameliorate early and later injury. This mini-review highlights our presentation at the 23rd International Conference on Advances in Critical Care Nephrology and UAB/UCSD O’Brien Center Acute Kidney Injury (AKI) Pre-Meeting.